Shanghai Zhongshan Hospital
826
152
182
129
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
1.2%
10 terminated/withdrawn out of 826 trials
92.8%
+6.3% vs industry average
12%
97 trials in Phase 3/4
2%
3 of 129 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (826)
Laparoscopic Staging for Stage III Gastric Cancer
Role: collaborator
Shanghai Clinical Cohort - Esophageal Cancer
Role: collaborator
BBAP With CS Mapping Guidance
Role: lead
Postoperative Anxiety and Depression Among Chinese Elderly Patients
Role: collaborator
Allogeneic Anti-CD7 CAR-T for Type 1 Diabetes
Role: lead
Association Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic Cancer
Role: lead
Prognostic Value of Metabolic Characteristics in High-Risk Populations for Acute Kidney Injury After Cardiac Surgery
Role: lead
Acute Myocardial Infarction Clinical Cohort
Role: lead
AI-ECG for Time-Resolved Prediction of HFrEF
Role: lead
Union-FAST: An Intelligent-Agent Intervention to Increase Antiviral Treatment Uptake in Diagnosed-but-Untreated Hepatitis B Patients
Role: collaborator
ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management
Role: lead
A Clinical Study on the Effect of Massaging Tian Tu Acupoint on Coughing After Esophageal Surgery
Role: lead
Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma
Role: lead
Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment
Role: lead
Acupuncture for Preventing Atrial Arrhythmia Recurrence After Ablation
Role: lead
Optimizing Endoscopic and Interventional Treatment for Portal Hypertensive Bleeding
Role: lead
HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma
Role: collaborator
Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma
Role: lead
CIED Post-OR Rehabilitation
Role: lead
To Evaluate the Feasibility and Safety of Combining Surgery (Pancreatectomy and Cytoreduction) With HIPEC for Treating Pancreatic Cancer With Peritoneal Involvement.
Role: collaborator